New therapeutic options in Alzheimer's disease;Nuevas opciones terapéuticas en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 42, Issue 8, 2006, Pages 478-481

  García Ruiz Espiga, Pedro J ^a,b   Echeverria A ^a   Garcia Torres A ^a   Contreras, A ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b Clínica Nuestra Señora de la Concepción   (Spain)

Author keywords

Alzheimer's disease; Ampakines; Cicloserine; Lithium; Memantine; Milacemide; Other non cholinergic treatments

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA TOCOPHEROL; AMPAKINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOSERINE; MEMANTINE; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID; SELEGILINE; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; ACETYLCHOLINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LITHIUM; MONOAMINE OXIDASE INHIBITOR;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEDICAL RESEARCH; NERVE DEGENERATION; REVIEW; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ACETAMIDES; ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; LITHIUM; MEMANTINE; MONOAMINE OXIDASE INHIBITORS; RECEPTORS, GLUTAMATE; SYNAPTIC TRANSMISSION;

EID: 33750134303     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4208.2005218     Document Type: Review

References (63)

1. Carlsson A, Lindquist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200.
2. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959; 11: 490-3.
3. Yahr M, Duvoisin R, Schear M, Barrett R, Hoehn M. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343-54.
4. Perry EK. The cholinergic system in old age and Alzheimer's disease. Age Ageing 1980; 9: 1-8.
5. Perry EK. The cholinergic hypothesis ten years on. Br Med Bull 1986; 42: 63-9.
6. Whitehouse PJ, Martino AM, Antuono PG. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986; 371: 146-51.
7. Palmer AM, Procter AW, Stratmann GC, Bowen DM. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 1986; 66: 199-204.
8. Kish SJ, El-Awar M, Schut L, Leach L, Oscar-Berman M, Freedman M. Cognitive deficits in olivopontocerebellar atrophy: implications for the cholinergic hypothesis of Alzheimer's dementia. Ann Neurol 1988; 24: 200-6.
9. Kish SJ, Robitaille Y, El-Awar M, Deck JH, Simmons J, Schut L, et al. Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy. Ann Neurol 1989; 26: 362-7.
10. DeKosky ST, Ikonoomovic MD, Styren SD, Beckett L, Wieniewski S, Bennet A, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51: 145-55.
11. Parnetti L, Senin U, Mecoci P. Cognitive enhancement therapy for Alzheimer's disease. Drugs 1997; 53: 752-68.
12. Scarpini L, Scheltens P, Felman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-47.
13. Francis P, Sims N, Procter AW, Bowen D. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspective. J Neurochem 1993; 60: 1589-601.
14. Greenamyre T, Porter R. Anatomy and physiology of glutamate in the CNS. Neurology 1994; 44 (Suppl 1): S7-13.
15. Lipton S, Rosenberg P. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994; 330: 613-21.
16. Dingledine R, McBain C. Glutamate and aspartate. In Siegel G, Agranoff B, Albers R, Fisher S, Uhler M, eds. Basic neurochemistry. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 316-33.
17. Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 1990; 4: 2745-52.
18. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S15-21.
19. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 2003; 17: 641-52.
20. 3H] MK-801 binding in Alzheimer's disease. J Neurochem 1989; 53: 698-740.
21. Martínez M, Frank A, Díez-Tejedor E, Hernanz A. Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J Neural Transm [Parkinson Dis Sect] 1993; 6: 1-9.
22. Antuono P, Jones J, Wang Y, Li JS. Decreased glutamate-glutamine in Alzheimer's disease detected in vivo with H.MRS at 0.5 T. Neurology 2001; 56: 737-42.
23. Zenon M, Hansson O, Chen N, Leavitt B, Brundin P, Hayden MR, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002; 33: 849-60.
24. Zeron M, Chen N, Moshaver A, Lee A, Wellington C, Hayden M, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001; 17: 41-53.
25. Bowen DM, Francis PT, Procter A. Treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1992; 55: 328.
26. Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clin Neuropharmacol 1995; 18: 28-38.
27. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. Dcycloserine enhances implicit memory in Alzheimer's patients. Neurology 1996; 46: 420-4.
28. Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999; 156: 467-9.
29. Herting RL. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann N Y Acad Sci 1991; 640: 237-40.
30. Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 1992; 40: 503-6.
31. Cutler NR, Fakouhi TD, Smith WT, Hendrie HC, Matsuo F, Sramek JJ, et al. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type. J Geriatr Psychiatry Neurol 1993; 6: 115-9.
32. Service RF. Will a new type of drug make memory-making easier? Science 1994; 266: 218-9.
33. Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998; 18: 2748-63.
34. Suppiramaniam V, Bahr BA, Sinnarajah S, Owens K, Rogers G, Yilma S, et al. Member of the ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors. Synapse 2001; 40: 154-8.
35. Hess US, Whalen SP, Sandoval LM, Lynch G, Gall CM. Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion. Neuroscience 2003; 121: 509-21.
36. Jarvis B, Figgit D. Memantine. Drugs Aging 2003; 20: 465-77.
37. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
38. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81-5.
39. Maskell P, Specter P, Newberry R, Bermúdez I. Inhibition of human α7 nicotinic acetylcholine receptors by open channel blocker of NMDA receptors. Br J Pharmacol 2003; 140: 1313-9.
40. Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease. Neurology 2001; 57: 1089-93.
41. Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
42. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
43. Selkoe D. The origins of Alzheimer disease: A is for amylod. JAMA 2000; 283: 1615-7.
44. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in normal aging: evidence for presyntomatic and very mild Alzheimer's disease. Neurology 1996; 46: 707-19.
45. Naslund J, Haroutunian V, Mosh R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7.
46. Schenk DB, Seubert P, Lieberburg I, Wallace J. Beta-peptide inmunization: a possible new treatment for Alzheimer disease. Arch Neurol 2000; 57: 934-6.
47. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after inmunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52.
48. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (and evidence-based review). Report of the quality standards subcommitte of the American Academy of Neurology. Neurology 2001; 56: 1154-66.
49. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline. Neurology 2000; 54: 1949-54.
50. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al, WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62.
51. Mulnard RA, Cotman CW, Kawas C, Van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283: 1007-15.
52. Muñoz-Montano JR, Moreno FJ, Ávila J, Díaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 1997; 411: 183-8.
53. Álvarez G, Muñoz-Montano JR, Satrústegui J, Ávila J, Bogóñez E, Díaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002; 4: 153-65.
54. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 281-90.
55. De Strooper B, Woogett J. Mental plaque removal. Nature 2003; 423: 392-3.
56. Phiel C, Wilson C, Lee V, Klein P. GSK-3 regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003; 423: 435-8.
57. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-2.
58. Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J Mol Neurosci 2002; 19: 303-7.
59. Veld B, Ruitenberg A, Hofman A, Launer L, Van Duijn C, Stijnen T, et al. Nonsteroideal antiinflamatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
60. McGeer P, Rogers J. Anti-inflamatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992; 42: 447-8.
61. Weggen S, Eriksen J, Das P, Wang R, Sagi S, Pietrzik C, et al. A subset of NSAIDS lower amyloidogenetic abeta 42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
62. Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM. Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther 2003; 307: 297-305.
63. Danysz W. CX-516 Cortex pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 1081-8.